JPRN-UMIN000003405已完成1 期
Safety and efficacy trial of accelerated partial breast irradiation with 3-dimentional conformal radiation therapy for stage 0, 1, and 2 breast cancer - APBI with 3D-CRT for breast cancer
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 71
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1) prior radiation therapy against the thoracic. 2) neoadjuvant chemotherapy and/or hormonal therapy 3) Infection with systemic therapy indicated. 4) Scleroderma, systemic lupus erythematosus, dermatomyositis 5) Women during pregnancy
研究者
相似试验
进行中（未招募）
1 期
clinical study to evaluate the efficacy and safety of a new drug (Bardoxolone methyl) in the treatment of subjects with Alport syndromeMedDRA version: 20.0Level: PTClassification code 10001843Term: Alport's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersAlport SyndromeEUCTR2016-004395-22-FRReata Pharmaceuticals, Inc.187
进行中（未招募）
1 期
clinical study to evaluate the efficacy and safety of a new drug (Bardoxolone methyl) in the treatment of subjects with Alport syndromeMedDRA version: 20.0Level: PTClassification code 10001843Term: Alport's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersAlport SyndromeEUCTR2016-004395-22-DEReata Pharmaceuticals, Inc.180
已完成
不适用
A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport SyndromeAlport SyndromeJPRN-UMIN000032448Reata Pharmaceuticals, Inc187
进行中（未招募）
1 期
clinical study to evaluate the efficacy and safety of a new drug (Bardoxolone methyl) in the treatment of subjects with Alport syndromeMedDRA version: 20.0Level: PTClassification code 10001843Term: Alport's syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersAlport SyndromeEUCTR2016-004395-22-ESReata Pharmaceuticals, Inc.187
进行中（未招募）
1 期
clinical study to evaluate the efficacy and safety of a new drug (Bardoxolone methyl) in the treatment of subjects with Alport syndromeAlport SyndromeEUCTR2016-004395-22-GBReata Pharmaceuticals, Inc.180